Pyxis Oncology Inc expected to post a loss of 51 cents a share - Earnings Preview

Pyxis Oncology

30/10/2023 13:26

* Pyxis Oncology Inc  PYXS.OQ   PYXS.O  is expected to show
no
change in quarterly revenue when it reports  results 
    * 
    * ​Refinitiv's mean analyst estimate for Pyxis Oncology Inc
is for
a loss of 51 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Pyxis
Oncology
Inc is $9​, above​ its last closing price of $1.57. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -0.64       -0.65      -0.41     Beat    36.7
 Mar. 31 2023  -0.90       -0.90      -0.55     Beat    38.8
 Dec. 31 2022              -0.93      -1.01     Missed  -8.7​
 Sep. 30 2022  -0.81       -0.81      -0.85     Missed  -4.5
 ​​Jun.        -0.75       -0.76      -0.79     Missed  -3.7
 30 2022                                                
 Mar. 31 2022  -0.61       -0.61      -0.97     Missed  -59.1​
 Dec. 31 2021              -0.37      -1.98     Missed  -442.1
 Sep. 30 2021  -0.51       -0.51      -8.96     Missed  -1,652
                                                        .6
 This summary was machine generated October 30 at 13:26 GMT.  All
figures in US dollars  unless otherwise stated